Teva Pharmaceutical Industries Limited (NYSE:TEVA) saw its share price trade relatively negative in the recent trading session. The share price was last updated to $50.98 with a loss of -0.99 points or -1.9%. The net money flow was $8.38 million and the up/down ratio was 1.22. Approximately $46.5 million was the inflow in upticks and $38.13 million was the outflow in downticks. On a weekly measure, the shares have seen a price change of -1.98%.The shares witnessed a block transaction with a net money flow of $10.38 million. The total money in uptick was $16.97 million and in downtick was $6.59 million with the up/down ratio reaching 2.57.
The stock has recorded a 20-day Moving Average of 3.38% and the 50-Day Moving Average is 4.23%. The company shares have dropped 13.09% in the past 52 Weeks. On July 28, 2015 The shares registered one year high of $72.31 and one year low was seen on May 12, 2016 at $49.51. The 50-day moving average is $52.43 and the 200 day moving average is recorded at $57.57. S&P 500 has rallied 1.93% during the last 52-weeks.
Teva Pharmaceutical Industries Limited (NYSE:TEVA): The stock opened at $52.04 on Tuesday but the bulls could not build on the opening and the stock topped out at $52.24 for the day. The stock traded down to $50.93 during the day, due to lack of any buying support eventually closed down at $50.98 with a loss of -1.90% for the day. The stock had closed at $51.97 on the previous day. The total traded volume was 5,208,143 shares.
Currently the company Insiders own 7.1% of Teva Pharmaceutical Industries Limited shares according to the proxy statements. Institutional Investors own 64.03% of Teva Pharmaceutical Industries Limited shares.
Teva Pharmaceutical Industries Limited (Teva) is a global pharmaceutical and drug company. The Companys generic products cover almost every major therapeutic area. The Company operates its business in two segments: Generic medicines, which manufactures and sells generic pharmaceutical products in several dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams, and Specialty medicines, which delivers solutions to patients and providers via medicines, devices and services. Its Central Nervous System (CNS) portfolio includes Copaxone, Azilect and Nuvigil. Its main respiratory medicines include ProAir hydrofluoroalkane, QVAR and Duoresp Spiromax. Its oncology portfolio includes Treanda, Trisenox, Granix Synribo, Lonquex, Tevagrastim/Ratiograstim, Myocet, Trisenox and Eporatio. Its womens health portfolio includes ParaGard, Plan B One-Step OTC/Rx (levonorgestrel) and Zoely.